Core Viewpoint - Marubi Biotechnology is seeking a dual listing in Hong Kong to enhance its capital strength and international financing capabilities, amid concerns over its financial health and high dividend payouts [2][4]. Group 1: Financial Performance and Pressures - Marubi's financial report indicates significant cash flow pressure, with a net cash outflow of 391 million yuan in Q3 2025, leading to a notable decrease in cash and cash equivalents [6]. - The company has short-term borrowings of 573 million yuan and total short-term liabilities of approximately 977 million yuan [8]. - Despite revenue growth, net profit growth has slowed, with a mere 2.13% increase in net profit attributable to shareholders in the first three quarters of 2025, while non-operating profit dropped by 5.42% [16]. Group 2: Dividend Policy and Shareholder Concerns - Marubi's dividend payout ratio has surged from 37.77% in 2019 to 202.82% in 2023, with a staggering 235.87% payout ratio in 2024, raising concerns among investors about the sustainability of such high dividends amid financial pressures [11]. - The majority of dividends benefit the founding couple, who hold over 80% of the shares, leading to investor worries about the prioritization of dividends over business reinvestment [11]. Group 3: Market Position and Competition - The competitive landscape in the domestic beauty industry is intensifying, with rising online traffic costs contributing to Marubi's struggle to increase profitability despite revenue growth [2]. - The company's reliance on online sales channels, which accounted for 87.6% of revenue in the first three quarters of 2025, has made it vulnerable to platform rules and rising costs [18]. Group 4: Technological Transformation and R&D Investment - Marubi is transitioning towards a biotechnology-focused beauty company, with significant investments in research and development, particularly in recombinant collagen products [20]. - However, R&D spending has not kept pace with sales expenses, with only a slight increase in R&D costs compared to a substantial rise in marketing expenses, indicating a potential imbalance in investment strategy [22].

Medical Aesthetics - Jiangsu Chuangjian Medical Technology Co., Ltd. received approval for its cross-linked recombinant collagen implant, marking a significant development in the medical aesthetics market [2][17] - The product is designed for facial dermal tissue filling to correct moderate to severe dynamic wrinkles, making it the fifth recombinant collagen implant approved in China and the first cross-linked version [17] - The recombinant collagen industry is shifting from "single type" to "diverse structure," with companies accelerating competition towards full-scenario applications [18] Cosmetics - Lin Qingxuan, a pioneer in the "oil-based skincare" segment, officially listed on the Hong Kong Stock Exchange, becoming the first high-end domestic skincare brand to go public [3][19] - The company has established a comprehensive supply chain system and a unique OMO (Online-Merge-Offline) channel model, which integrates online and offline sales to enhance customer engagement and drive growth [23][35] - Lin Qingxuan's flagship product, the camellia oil essence, has achieved a leading repurchase rate of 33.5% in the industry, indicating strong customer loyalty [27][46] Investment Recommendations - The company recommends focusing on differentiated upstream medical aesthetics product manufacturers and chain medical institutions, highlighting the potential of Meili Tianyuan Medical Health [4][48] - In the cosmetics sector, the emphasis is on domestic brands that innovate in emotional value and safe ingredients, with key recommendations including Lin Qingxuan and other brands that leverage both online and offline channels [4][47] Market Performance - In December, the beauty and personal care index fell by 1.70%, underperforming the broader market, while the medical aesthetics sector saw notable gains from companies like Meili Tianyuan Medical Health and Jinbo Biological [5][10] - For the full year of 2025, the medical aesthetics sector showed mixed performance, with companies like Sihuan Pharmaceutical and Yonghe Medical leading in growth [10] Financial Highlights - Lin Qingxuan reported a total revenue of 1.05 billion yuan in the first half of 2025, reflecting a year-on-year growth of 98.3%, primarily driven by its camellia oil essence [23][41] - The company's gross margin remains high at 82.4%, with specific product categories like essence oil achieving even higher margins [23][41]

Investment Rating - The industry investment rating is "Positive" (首次) [1] Core Insights - The beauty and personal care industry is experiencing a mixed performance, with the beauty care index declining by 1.70% in December 2025, ranking 24th among all primary industries [15] - The medical beauty sector is seeing innovation with the approval of new products, such as the cross-linked recombinant collagen implant by Jiangsu Chuangjian Medical Technology Co., which is expected to inject new momentum into the market [7][34] - Lin Qingxuan, a pioneer in the "oil-based skincare" segment, has successfully listed on the Hong Kong Stock Exchange, marking a significant milestone for domestic high-end skincare brands [8][39] Summary by Sections Market Review - In December, the beauty care index reported a decline of 1.70%, underperforming the broader market, which saw the Shanghai Composite Index increase by 2.06% [15] - For the entire year of 2025, the beauty care index showed a cumulative increase of 0.39%, again lagging behind the Shanghai Composite Index's 18.41% growth [15] Medical Beauty - Jiangsu Chuangjian Medical's cross-linked recombinant collagen implant has been approved, making it the fifth such product in China and the first cross-linked version [34] - The industry is shifting from single product competition to a full-chain layout, with companies like Jinjian Biological and Junzi Biological also making significant advancements in the recombinant collagen space [34][36] Cosmetics - Lin Qingxuan has established itself as a leader in the high-end domestic skincare market, achieving the highest retail sales among domestic brands in 2024 [39] - The company has built a comprehensive supply chain and employs an OMO (Online-Merge-Offline) model to enhance customer engagement and sales [39][49] - Lin Qingxuan's core product, the camellia oil essence, has a high repurchase rate of 33.5%, indicating strong customer loyalty [51] Investment Recommendations - The report recommends focusing on differentiated upstream medical beauty product manufacturers and chain medical beauty institutions, highlighting companies like Meili Tianyuan Medical Health and Aimeike [9][53] - In cosmetics, the report suggests investing in brands that innovate in emotional value and safe ingredients, with a focus on domestic brands like Maogeping and Lin Qingxuan [54]

Core Insights - Hyaluronic acid, once costly and referred to as "liquid gold," has seen significant technological advancements in production, particularly by the company Furuida, which has transitioned from animal extraction to microbial fermentation and synthetic biology [1][4] - Furuida has become a key player in the global hyaluronic acid market, controlling 70% of the raw material supply, and is recognized as a driving force behind the industry's innovation and upgrade [1][4] Technological Breakthroughs - Furuida emphasizes that raw material innovation is crucial for industry upgrades, positioning it as the foundation for pharmaceutical and cosmetic development [4] - The company has achieved a significant milestone by being recognized as the "global pioneer in biosynthetic royal jelly acid," marking a transition from theoretical validation to industrial application [4] - Furuida's collaboration with Qilu University of Technology has led to the successful development of a microbial cell factory for efficient production of royal jelly acid, shifting from reliance on scarce natural resources to sustainable manufacturing [4] Industry Expansion - Furuida is actively expanding its raw material portfolio, including the acquisition of international hyaluronic acid leaders and entering the fragrance sector through strategic mergers [8] - The company has established a collaborative matrix of six subsidiaries focused on cosmetic and pharmaceutical raw material development, enhancing its global competitive advantage [8] - Furuida has achieved key regulatory milestones, including the registration of Class III medical device raw materials and the approval of A-class raw materials for pharmaceuticals, validating its R&D capabilities and quality management [8][9] Product Development and Market Strategy - Furuida is implementing a "5+N" brand development strategy, focusing on various skincare and medical fields, and has successfully launched several well-known brands [10] - The company has created a comprehensive product matrix in the medical health sector, maintaining competitive market positions in ophthalmology, orthopedics, dermatology, and gynecology [10] Talent and Innovation - Continuous R&D investment and a systematic talent strategy are central to Furuida's innovation in raw materials and products [13] - The establishment of a provincial-level research platform and partnerships with universities enhances Furuida's R&D capabilities and talent cultivation [13][14] - Furuida's products are now exported to 79 countries, supported by various international certifications, establishing a strong foundation for global market entry [14]

Group 1 - The core viewpoint of the article highlights the positive performance of the healthcare sector, particularly in the fields of collagen and skincare products, with significant growth opportunities identified [1] - The Medical Industry ETF (159877.SZ) increased by 4.05%, and Lepu Medical surged by 19.99%, indicating strong market interest and investor confidence in the sector [1] - Jianghai Securities emphasizes the multi-dimensional investment logic in the healthcare industry, particularly in the collagen sector, where new entrants like Chuangjian Medical are gaining traction with their cross-linked collagen implants [1] Group 2 - The approval of cross-linked collagen products by Chuangjian Medical positions it as a strong competitor in the market, following the successes of Jinbo Biology and Juzhi Biology [1] - The "oil-based skincare" segment is projected to see sales exceeding 9.5 billion yuan from March 2024 to February 2025, reflecting a 36% growth, driven by advancements in domestic brands [1] - Continuous improvements in ingredients, technology, and formulations are enhancing industry standards, further propelling growth in the healthcare sector [1]

枭雄要成就霸业，需要的不只是一招鲜，而是长期源源不断的竞争力。 陕西女首富范代娣和前山东女首富赵燕，如果不做医美，不关注护肤成分，你可能对这两个名字并不熟 悉。但在如今的中国商业版图上，这两位女性，分别掌控着两家市值几百亿的上市公司——巨子生物和 华熙生物。 表面上看，她们一个在西安，一个在山东；一个做蛋白，一个做多糖；一个出身严谨的大学实验室，一 个来自野蛮生长的地产江湖。她们本该井水不犯河水。 但现实是，这两家公司正在进行一场旷日持久的、甚至可以说是「你死我活」的商战。 但命运和机遇有时候就是不讲道理。 这一年，在北大EMBA的课堂上，她结识了山东省生物药物研究院的副院长郭学平。他跟赵燕说了一句 至今被奉为行业金句的话：「一个玻尿酸分子，能锁住1000个水分子。」 故事的起点，要回到2000年。 这是一个神奇的年份，两人的命运在这一年同时被改写。 当时的赵燕，还是一个在海南淘金成功、在北京开发楼盘的地产大鳄。后来更是在北京开发了中环世贸 中心，承建了奥运会场馆五棵松体育馆，也就是现在的五棵松华熙Live。 按理来说，她的头衔，应该是地产女王，而不是现在的「玻尿酸女王」。 01 她没有亲自去搞研发，而是用资 ...

Core Insights - Jiangsu Chuangjian Medical's "cross-linked recombinant collagen implant" has been approved by the National Medical Products Administration, marking a significant milestone in the domestic regenerative collagen market [1][12] - The medical aesthetics industry is shifting from simple volume filling to advanced needs for tissue regeneration, with regenerative materials like collagen gaining popularity due to their ability to stimulate the body's own collagen production [1][6] Market Overview - The Chinese medical aesthetics injection market is projected to grow from 21.2 billion RMB in 2023 to 65.3 billion RMB by 2028, with a compound annual growth rate (CAGR) of 25.3% [5] - The regenerative anti-aging injection segment is expected to increase its market share from 3% in 2019 to 31% by 2028, indicating it is the fastest-growing sub-market [5][6] Product Categories - Medical aesthetic injectables can be categorized into hyaluronic acid, botulinum toxin, and regenerative anti-aging materials, with the latter focusing on long-term tissue regeneration rather than just physical filling [3][4] - Regenerative anti-aging injectables are further divided into microsphere regeneration, collagen-based, PDRN, and other categories, emphasizing their role in improving skin quality and addressing aging [4][5] Competitive Landscape - The domestic market for regenerative anti-aging injectables is characterized by a mix of domestic and imported products, with companies like Jinjian Biological, Juzi Biological, and Chuangjian Medical forming a competitive triad [7][12] - As of 2025, there are 15 approved collagen implant products in China, with a notable presence of both animal-derived and recombinant collagen products [10][11] Innovation and Development - Companies are focusing on R&D and regulatory compliance to enhance product quality and market acceptance, with a trend towards stricter approval processes for medical devices [13][14] - Innovations in collagen types and structures are crucial for clinical applications, with companies like Chuangjian Medical achieving significant advancements in the stability and effectiveness of their products [17] Future Trends - The integration of recombinant collagen with microsphere components is expected to create new product forms and market opportunities, positioning domestic companies to play a more significant role in the global medical aesthetics market [19]

Investment Rating - Industry rating: "Accumulate" (maintained) [7] Core Insights - The approval of the cross-linked recombinant collagen implant by Chuangjian Medical on December 23, 2025, marks a significant addition to the recombinant collagen industry, which is expected to expand further [7] - Lin Qingxuan has passed the Hong Kong Stock Exchange listing hearing, potentially becoming the first high-end domestic skincare stock in Hong Kong [7] - The "oil-based skincare" brand Afu released the industry's first technical standard for functional skincare products on December 8, 2025, supporting the standardized development of the "oil-based skincare" sector [7] Summary by Sections Industry Performance - Over the past 12 months, the industry has shown a relative return of -21.5% compared to the CSI 300 index, with absolute returns of -4.52% [3] Key Events - Chuangjian Medical's recombinant collagen implant is composed of cross-linked recombinant collagen hydrogel and is approved for facial dermal filling to correct moderate to severe dynamic wrinkles [7] - Lin Qingxuan's core product, camellia oil essence, has seen its revenue share increase from 31.5% in 2022 to an expected 45.5% in the first half of 2025, maintaining its position as the top-selling facial essence oil in China for 11 consecutive years [7] Investment Recommendations - The successful approval of Chuangjian Medical's product is expected to enhance industry growth, with a recommendation to monitor the product's market performance post-launch [7] - The sales of essence oils across major online platforms are projected to exceed 9.5 billion yuan from March 2024 to February 2025, with facial essence oils experiencing a 36% growth, indicating a strong market demand [7]

摘要 创建公司推出交联重组胶原蛋白填充剂，采用独特 474 个氨基酸序列， 提供多种规格预灌封注射器包装，旨在与现有非交联产品及部分动物来 源胶原蛋白市场竞争，凭借即刻维持时间和形态优势，有望成为微整形 领域新选择，但市场表现需进一步观察。 业内普遍认为创建公司的交联技术成熟，安全性是关注点，消费者态度 复杂，期望长效但对潜在风险谨慎。机构推荐和安全性报告是消费者接 受的关键。该技术自主研发，已应用于疫苗等领域，关键在于杂质控制 和工艺流程管理，需持续改进生产工艺及严格质量控制。 创建公司医美团队月白知己由张笑红领导，拥有丰富的皮肤科产品代理 经验和客户资源，产品主要通过代理商渠道销售，覆盖皮肤科和部分注 射科室。未来大型连锁倾向成熟品牌，新氧倾向独家定制，中小机构倾 向低成本引流产品。 重组胶原蛋白被视为下一个潜力市场，未来将有多种类型和规格产品获 批。序列越长风险越高，需权衡序列长度与安全性。短序列在提纯和生 产中更简便，更具成本优势。非天然片段的引入主要为方便生产和降低 成本，实际效果需临床验证。 Q&A 创建公司最近获得的三型胶原蛋白证书有哪些特别之处？它在市场运营中可能 会如何定位和推广？ 创建公司 ...

Group 1: Core Insights - Kexing Pharmaceutical is entering the rapidly growing recombinant collagen market, with a clinical trial for its type III humanized collagen product officially launched [1][2] - The recombinant collagen market in China is projected to reach 108.3 billion yuan by 2027, with a compound annual growth rate of 44.93% [1][2] - Kexing Pharmaceutical's revenue has stagnated around 1.2 billion yuan for several years, making this strategic shift a necessary move for growth [1][6] Group 2: Industry Trends - The recombinant collagen is becoming a new favorite in the medical aesthetics sector, with its market share expected to grow significantly, while hyaluronic acid's market share is declining [2][4] - Currently, only Jinbo Biotech has received approval for two type III medical devices in this space, indicating a competitive landscape that is likely to change as more companies enter [2][4] Group 3: Company Challenges - Kexing Pharmaceutical faces challenges in cash flow, with net cash flow being negative from 2022 to mid-2025, and cash reserves decreasing from 784 million yuan to 446 million yuan [4][11] - The company is also under pressure from increasing competition, with several firms, including major beauty brands, entering the recombinant collagen market [4][11] Group 4: Historical Context - Kexing Pharmaceutical and Kexing Biology share a common origin, having been established from the same foundational institutions, but have diverged significantly in their paths over the past 30 years [7][8] - Kexing Biology has faced governance issues and financial struggles, while Kexing Pharmaceutical has been criticized for its stagnant revenue and reliance on legacy products [8][11]